FDA Pediatric Oncology Advisors Seek Meaningful Trial Plans For Mutually Beneficial Review
This article was originally published in The Pink Sheet Daily
Executive Summary
As the message that pediatric trials may be necessary or required has apparently gotten across to industry, ODAC’s Pediatric Subcommittee is ready to advise developers on trials that might help improve the way pediatric cancer drugs are developed. Nominations are being accepted for its December meeting.
You may also be interested in...
Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies
FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.